Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Trial Profile

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 01 Sep 2017 Results assessing Pharmacokinetics of apatinib in healthy Caucasian, Japanese and Chinese subjects following a single-dose administration, were published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top